BWX Technologies

BWXT Q3 2025 Earnings

Reported Nov 3, 2025 at 4:19 PM ET · SEC Source

Q3 25 EPS

$1.00

BEAT +16.55%

Est. $0.86

Q3 25 Revenue

$866.3M

BEAT +8.75%

Est. $796.6M

vs S&P Since Q3 25

-1.7%

TRAILING MARKET

BWXT +5.1% vs S&P +6.7%

Market Reaction

Did BWXT Beat Earnings? Q3 2025 Results

BWX Technologies turned in a standout third quarter for fiscal 2025, posting earnings per share of $1.00 against a consensus estimate of $0.86, a beat of 16.55%, while revenue surged 28.9% year-over-year to $866.29 million, clearing Wall Street's $79… Read more BWX Technologies turned in a standout third quarter for fiscal 2025, posting earnings per share of $1.00 against a consensus estimate of $0.86, a beat of 16.55%, while revenue surged 28.9% year-over-year to $866.29 million, clearing Wall Street's $796.60 million estimate by 8.75%. The outperformance was anchored by an explosive quarter in Commercial Operations, where revenue more than doubled to $251.00 million on higher nuclear components, field services, and contributions from the Kinectrics acquisition, complementing steady 10% growth in the core Government Operations segment. Perhaps the most striking figure was BWXT's record backlog of $7.39 billion, up 119% year-over-year, a reflection of what management called an unprecedented demand environment across defense, clean energy, and medical nuclear markets. Free cash flow swung to $94.90 million from negative $7.70 million a year ago, adding financial credibility to the growth story. Encouraged by the momentum, management raised its 2025 non-GAAP EPS guidance to $3.75–$3.80 and set full-year revenue above $3.10 billion, while introducing a preliminary 2026 outlook targeting low-double-digit to low-teens adjusted EBITDA growth.

Key Takeaways

  • Higher naval nuclear component production volumes
  • Special materials processing growth with large multi-year contracts
  • Contribution from A.O.T. and Kinectrics acquisitions
  • Higher commercial nuclear components, field services, and fuel handling revenue
  • Higher medical sales
  • Strong working capital management and timing of awards driving cash flow improvement
  • Record backlog of $7.4 billion, up 119% YoY
24/7 Wall St

BWXT YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

24/7 Wall St

BWXT Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q4 25

“We delivered strong financial results in the third quarter of 2025 including double-digit organic revenue growth and healthy free cash flow. Further, we posted another quarter of robust bookings, driven by large, multi-year special materials contracts highlighting the trust our customers put in BWXT and the power in our differentiating nuclear credentials.”

— Rex D. Geveden, Q3 2025 Earnings Press Release